The News Review:

- Cardio Care Guidelines Backed by Weak Evidence
- Durham’s Cato Research invests in Cordex Pharma
- Crescendo(tm) the Clinical and Translational Research Exchange …
- Cancer Center Profile: Dana-Farber/Harvard Cancer Center
- Micromet Adds Former Head of Roche ncology Kapil Dhingra MD to …

Cardio Care Guidelines Backed by Weak Evidence
MedPage Today NJ -
Point out that the researchers called for increased funding for clinical research especially for comparative effectiveness trials. Among guidelines for specific diseases intervention and diagnostic techniques only 9. 4% of recommendations were based on conclusive data from multiple randomized trials — the highest level of evidence. The findings were reported in the Feb. 25 edition of the Journal of the American Medical Association by Pierluigi Tricoci M.

Durham’s Cato Research invests in Cordex Pharma
Bizjournals.com NC -
biotechnology firm. The deal calls for Cato Research to handle regulatory work and clinical testing of Cordex’s drugs. Cato would be compensated in part with stock ownership in Cordex.

Crescendo(tm) the Clinical and Translational Research Exchange …
PR Web (press release) WA -
Crescendo services fall into three major categories: 1. Support for Multi-Center Clinical Trials2. Establishment of Metrics & Benchmarks for Clinical Research perations3. Creation & Utilization of Research RegistriesSupport for Multi-Center Clinical TrialsServices in this category provide the infrastructure to easily launch highly secure often transitory.

Cancer Center Profile: Dana-Farber/Harvard Cancer Center
National Cancer Institute – NCI Cancer Bulletin MD -
Beth Israel Deaconess Medical CenterBrigham and Women’s HospitalChildren’s Hospital BostonDana-Farber Cancer InstituteHarvard Medical SchoolHarvard School of Public HealthMassachusetts General HospitalMember institutions combine their scientific strengths to accelerate research findings from the laboratory clinical research trials and studies of populations enhancing patient care and our understanding of the underlying causes of cancer. The Center currently supports 17 established disease- and discipline-based research programs as well as 10 developing programs.
Related from Yumafrogs: Cancer support center invites Yuma to open house

Micromet Adds Former Head of Roche ncology Kapil Dhingra MD to …
FXBusiness -
Dhingra’s appointment the Board is now comprised of nine members. Dhingra has been active in oncology clinical research for over 20 years. During his tenure at Hoffmann-La Roche from 1999 to 2008 he built the largest oncology clinical development department in the industry. Dhingra provided strategic development leadership resulting in a successful track record of global oncology drug approvals including numerous indications for Herceptin(R) MabThera(R) Xeloda(R) Bondronat(R) Tarceva(R) and Avastin(R). In his academic career Dr.